SM
BBIO icon

SCGE Management’s BridgeBio Pharma BBIO Stock Holding History

SCGE Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-415,978
Closed -$8.93M – 24
2019
Q3 		$8.93M Sell
415,978
-172,257
-29% -$4.77M 0.45% 21
2019
Q2 		$15.9M Buy
+588,235
New +$16M 0.79% 20

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

SCGE Management's BBIO Position: Q4 2019 in Review

SCGE Management sold out of BridgeBio Pharma (BBIO) in Q4 2019, closing a stake of 415,978 shares — an estimated $8.93M sold.

SCGE Management first reported a position in BBIO in Q2 2019 and held it in 2 quarters. The position peaked at $15.9M in Q2 2019. 88 funds tracked by Wall St. Rank hold BBIO as of Q4 2019.

  • SCGE Management reported no remaining BridgeBio Pharma position as of Q4 2019 after selling out during the quarter.
  • SCGE Management sold 415,978 BridgeBio Pharma shares in Q4 2019, an estimated $8.93M.
  • SCGE Management first reported a position in BridgeBio Pharma in Q2 2019 and held it in 2 quarters.
  • SCGE Management's BridgeBio Pharma position peaked at $15.9M in Q2 2019.
  • 88 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2019.

Based on SCGE Management's 13F filing for Q4 2019, filed 14 Feb 2020.